Event-Driven Stocks

Humacyte, Inc.

HUMANasdaq

Healthcare · Biological Products, (No Diagnostic Substances) · DE · SEC filings ↗ · Compare ⊕

View price & chart on Yahoo Finance ↗
Signs● 5 warning● 1 severedetails ↓

Financials

SEC XBRL · annual
 FY25FY24FY23FY22FY21FY20
Revenue$2.0M$0————
Operating income−$108.1M−$114.4M−$100.0M−$84.6M−$81.2M−$64.6M
Net income−$40.8M−$148.7M−$110.8M−$12.0M−$26.5M−$66.5M
Total assets$116.4M$137.9M$128.2M$204.3M$286.5M$106.7M
Total liabilities$113.3M$190.5M$114.7M$87.4M$164.4M$36.0M
Equity$3.1M−$52.7M$13.5M$116.9M$122.2M−$350.3M
EPS (diluted)$-0.26$-1.26$-1.07$-0.12$-0.66$-11.54
Shares out.155.1M119.1M103.3M103.0M103.0M5.8M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2025
Operating margin
−5306.0%
Net margin
−2003.6%
Return on equity
−1313.4%
Return on assets
−35.1%
Return on capital (ROCE)
−110.4%
Liabilities / assets
97.3%
Debt / equity
36.43×
Book value / share
$0.02
Revenue growth (YoY)
—
Net income growth (YoY)
—

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2025
Altman Z″ (distress)
-23.79distress
Accruals / assets
55.2%high accruals
Piotroski F-Score
4/8mixed

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
29
/ 100
Profitability 0Growth n/aCatalyst 67Earnings quality 0Financial strength 50

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.

Signs

● 1 severe● 5 warning● 0 good
  • Altman Z″ in the distress zone
  • Operating losses (negative operating margin)
  • Reported a net loss
  • High leverage (liabilities > 70% of assets)
  • Negative operating cash flow
  • High accruals — earnings-quality risk

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

Clinical trials

ClinicalTrials.gov · ongoing · next readout first

Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.

5%+ owners

SEC Schedule 13D / 13G · last 3 yrs

Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.

Short interest

FINRA · bi-monthly
SettlementShares shortDays to coverΔ vs prior
May 15, 202641.2M5.2-7.9%
Apr 30, 202644.7M10.0-0.3%
Apr 15, 202644.8M9.4+6.2%
Mar 31, 202642.2M3.0+3.8%
Mar 13, 202640.7M10.4+6.6%

Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (3)

Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.